Essai Clinique

Généré le 16 mai 2024 à partir de

Titre	Étude de phase I sur le BMS-986416, seul et en association avec le nivolumab, dans le traitement de certaines tumeurs solides
Protocole ID	CA102-003
ClinicalTrials.gov ID	NCT04943900
Type(s) de cancer	Tumeurs solides
Phase	Phase I
Type étude	Clinique
Médicament	BMS-986416 seul ou en association avec le nivolumab
Institution	CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
Ville	
Investigateur principal	Dre Rahima Jamal
Coordonnateur	Adeline Hamon 514-890-8000 poste 30737
Statut	Actif en recrutement
But étude	The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select advanced solid tumors.
Critères d'éligibilité	• Participants with histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent select solid tumor • Eligible tumor types Non-small cell lung cancer (NSCLC), Urothelial carcinoma (UC), Squamous cell carcinoma of the head and neck (SCCHN), Hepatocellular carcinoma (HCC), Microsatellite-stable colorectal carcinoma (MSS CRC), or Pancreatic ductal adenocarcinoma (PDAC) • Resistant/refractory to or intolerant of existing standard therapies known to provide clinical benefit • Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) • Disease amenable to serial biopsy
Critères d'exclusion	• Uncontrolled or significant cardiovascular disease • Known connective tissue disease such as Marfan, Ehlers-Danlos, or Loeys-Dietz syndrome • Medical requirement for chronic anticoagulant or antiplatelet agents (except low-dose aspirin, which is permitted) Other protocol-defined inclusion/exclusion criteria apply